Nubeqa, an androgen receptor inhibitor, was approved for the treatment of patients with nmCRPC based on data from the placebo-controlled phase 3 ARAMIS trial.
With the advent of more reliable and accurate ways to screen for prostate cancer, such as PSA testing and prostate MRI, the authors argue that it is time to stop the “antiquated practice” of the digital rectal examination.
The FDA is alerting clinical laboratory staff and health care providers regarding the risk of false negative results with any SARS-CoV-2 test if a mutation occurs in the part of the virus’ genome assessed by that test.
In a study of men on active surveillance for localized prostate cancer, each 1-unit increase in Mediterranean diet score, calculated based on patients’ baseline food frequency questionnaire information, was associated with a 12% decreased risk for Gleason grade group progression.